Literature DB >> 29173002

miR-509-3p promotes cisplatin-induced apoptosis in ovarian cancer cells through the regulation of anti-apoptotic genes.

Wei Chen1, Jingjie Du2, Xiaodi Li2, Jiancheng Su2, Yongzhi Huang3, Nan Ding3, Mengdie Zhang2, Songshan Jiang2.   

Abstract

AIM: Previous observations have implicated miR-509-3p's ability in regulating cisplatin-triggered apoptosis in ovarian cancer. However, the underlying mechanisms were not fully understood. MATERIALS &
METHODS: The roles of miR-509-3p in cellular apoptosis were assessed through MTT and DAPI assays. The confirmation of the regulation of BCL2 family members by miR-509-3p was investigated by luciferase reporter assay, western blot, quantitative real-time PCR and rescue experiments.
RESULTS: MiR-509-3p can decrease the IC50 values of cisplatin and promote apoptosis in ovarian cancer cells. Furthermore, on a panel of anti-apoptotic proteins, we identified that miR-509-3p could regulate BCL2, BCL2L2 and MCL1 via their 3'UTRs.
CONCLUSION: Our study demonstrates that miR-509-3p could sensitize ovarian cancer cells to cisplatin treatment by targeting multiple anti-apoptosis genes including BCL2.

Entities:  

Keywords:  BCL2; apoptosis; microRNA-509-3p; ovarian cancer

Mesh:

Substances:

Year:  2017        PMID: 29173002     DOI: 10.2217/pgs-2017-0115

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  12 in total

1.  FPOA induces apoptosis in HeLa human cervical cancer cells through a caspase-mediated pathway.

Authors:  Xin Li; Tolgor Bau; Haiying Bao
Journal:  Oncol Lett       Date:  2018-03-29       Impact factor: 2.967

2.  Long noncoding RNA CBR3 antisense RNA 1 promotes the aggressive phenotypes of non‑small‑cell lung cancer by sponging microRNA‑509‑3p and competitively upregulating HDAC9 expression.

Authors:  Yun Guan; Juan Yang; Xinmei Liu; Lijuan Chu
Journal:  Oncol Rep       Date:  2020-08-07       Impact factor: 3.906

3.  The ovarian germinal reserve and apoptosis-related proteins in the infant and adolescent human ovary.

Authors:  María Itatí Albamonte; Mirta Susana Albamonte; Ricardo M Bou-Khair; Luis Zuccardi; Alfredo Daniel Vitullo
Journal:  J Ovarian Res       Date:  2019-03-11       Impact factor: 4.234

4.  The Expression and Effection of MicroRNA-499a in High-Tobacco Exposed Head and Neck Squamous Cell Carcinoma: A Bioinformatic Analysis.

Authors:  Shi-Qi Gong; Meng Xu; Ming-Liang Xiang; Ya-Min Shan; Hao Zhang
Journal:  Front Oncol       Date:  2019-07-31       Impact factor: 6.244

Review 5.  BCL-w: apoptotic and non-apoptotic role in health and disease.

Authors:  Mariusz L Hartman; Malgorzata Czyz
Journal:  Cell Death Dis       Date:  2020-04-21       Impact factor: 8.469

6.  Expression of the chrXq27.3 miRNA cluster in recurrent ovarian clear cell carcinoma and its impact on cisplatin resistance.

Authors:  Kosuke Yoshida; Akira Yokoi; Mai Sugiyama; Shingo Oda; Kazuhisa Kitami; Satoshi Tamauchi; Yoshiki Ikeda; Nobuhisa Yoshikawa; Kimihiro Nishino; Kaoru Niimi; Shiro Suzuki; Fumitaka Kikkawa; Tsuyoshi Yokoi; Hiroaki Kajiyama
Journal:  Oncogene       Date:  2021-01-08       Impact factor: 9.867

Review 7.  Double Insurance for OC: miRNA-Mediated Platinum Resistance and Immune Escape.

Authors:  Xueqin Zou; Yangjing Zhao; Xiuting Liang; Hui Wang; Yanling Zhu; Qixiang Shao
Journal:  Front Immunol       Date:  2021-04-01       Impact factor: 7.561

Review 8.  MicroRNAs as the critical regulators of Cisplatin resistance in ovarian cancer cells.

Authors:  Meysam Moghbeli
Journal:  J Ovarian Res       Date:  2021-09-30       Impact factor: 4.234

Review 9.  Resistance to cis- and carboplatin initiated by epigenetic changes in ovarian cancer patients.

Authors:  Heidi Schwarzenbach; Peter B Gahan
Journal:  Cancer Drug Resist       Date:  2019-06-19

10.  MicroRNA miR-509-3p inhibit metastasis and epithelial-mesenchymal transition in hepatocellular carcinoma.

Authors:  Huiming Zhang; Shuang Liu; Liqiang Chen; Yanliang Sheng; Wenzhe Luo; Gang Zhao
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.